Trial Profile
Short Course Daratumumab in Minimal Residual Disease (MRD) Positive Myeloma Patients After Induction Therapy With/Without Consolidative High Dose Chemotherapy/Autologous Stem Cell Support
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 Mar 2023 Status changed from active, no longer recruiting to completed.
- 08 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 05 May 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.